Print Page      Close Window     

Investors

SEC Filings

6-K
OBSEVA SA filed this Form 6-K on 03/30/2018
Entire Document
 


LOGO

 

NOLASIBAN Phase 3 clinical trial protocol (IMPLANT2) 41 fertility centers in 9 European countries Main Study Primary Analysis Follow-Up 10 week 1 month pregnancy rate Not preg. FU 900 mg, n=380 D3 or D5 SCREENING IVF/ICSI ET Placebo, n=380 7–8 months 6 months Preg.* Randomize Preg. FU Neonatal FU n=314 * Estimate Target enrollment of 760 patients • Trial conducted in Europe FPI March 2017 – Recruitment completed August 2017 –Top Line Results February 2018 28 Note: N=760 gives 90% power to show significant difference if the true effect size is 11-12%. It will still show a significant 27 effect if the observed size is about 6-7%.